Business Wire | Nov 24, 2020 04:01PM EST

Deciphera Pharmaceuticals, Inc. to Participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference

Nov. 24, 2020

WALTHAM, Mass.--(BUSINESS WIRE)--Nov. 24, 2020--Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a commercial-stage biopharmaceutical company developing innovative medicines to improve the lives of people with cancer, today announced that Steve Hoerter, President and Chief Executive Officer, has participated in a fireside chat in advance of the Piper Sandler 32nd Annual Virtual Healthcare Conference, being held December 1-3, 2020.

A recording of the fireside chat is now available on the "Events and Presentations" page in the "Investors" section of the Company's website at https://investors.deciphera.com/news-events/events-presentations and will be available for 90 days.

About Deciphera Pharmaceuticals

Deciphera is a biopharmaceutical company focused on discovering, developing and commercializing important new medicines to improve the lives of people with cancer. We are leveraging our proprietary switch-control kinase inhibitor platform and deep expertise in kinase biology to develop a broad portfolio of innovative medicines. In addition to advancing multiple product candidates from our platform in clinical studies, QINLOCK(r) is Deciphera's FDA-approved switch-control kinase inhibitor for the treatment of fourth-line gastrointestinal stromal tumor (GIST). QINLOCK is also approved for fourth-line GIST in Canada and Australia. For more information, visit www.deciphera.com and follow us on LinkedIn and Twitter (@Deciphera).

View source version on businesswire.com: https://www.businesswire.com/news/home/20201124005973/en/

CONTACT: Contacts: Investor Relations: Jen Robinson Deciphera Pharmaceuticals, Inc. jrobinson@deciphera.com 781-906-1112

CONTACT: Media: David Rosen Argot Partners David.Rosen@argotpartners.com 212-600-1902